Success Metrics

Clinical Success Rate

100.0%

Based on 6 completed trials

Completion Rate

100%(6/6)

Active Trials

0(0%)

Results Posted

50%(3 trials)

Phase Distribution

Ph phase_1

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Phase 1Safety & dosage

6(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(6)

Detailed Status

Completed6

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 1

Trials by Phase

Phase 16 (100.0%)

Trials by Status

completed6100%

Recent Activity

0 active trials

Showing 5 of 6

completedphase_1

Clinical Trials (6)

Showing 6 of 6 trials

NCT05043766Phase 1

Evaluation of Oral PF614 Relative to OxyContin (PF614-102)

Completed

NCT03403504Phase 1

OTR Tablet 10 mg Fasted-state Bioequivalence Study

Completed

NCT03398278Phase 1

OTR Tablet 40 mg Fasted-state Bioequivalence Study

Completed

NCT03398330Phase 1

OTR Tablet 40 mg Fed-state Bioequivalence Study

Completed

NCT03475862Phase 1

Nasal Human Abuse Potential of PTI-821

Completed

NCT01557257Phase 1

Pharmacokinetics Study of ALO-02 and OxyContin

Completed

All 6 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 6